chr17-63951483-C-A
Variant summary
Our verdict is Likely pathogenic. The variant received 7 ACMG points: 7P and 0B. PM2PM5PP2PP3_Moderate
The NM_000334.4(SCN4A):c.2794G>T(p.Asp932Tyr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000137 in 1,459,686 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D932N) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000334.4 missense
Scores
Clinical Significance
Conservation
Publications
- hyperkalemic periodic paralysisInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P, Orphanet
- paramyotonia congenita of Von EulenburgInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Laboratory for Molecular Medicine, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P, Orphanet
- SCN4A-related myopathy, autosomal recessiveInheritance: AR Classification: DEFINITIVE Submitted by: Illumina, ClinGen
- hypokalemic periodic paralysis, type 2Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- potassium-aggravated myotoniaInheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- congenital myasthenic syndrome 16Inheritance: AR Classification: STRONG, LIMITED Submitted by: PanelApp Australia, Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- congenital myopathyInheritance: AR Classification: STRONG Submitted by: Genomics England PanelApp
- congenital myopathy 22A, classicInheritance: AR Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- acetazolamide-responsive myotoniaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- hypokalemic periodic paralysisInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- myotonia fluctuansInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- myotonia permanensInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- postsynaptic congenital myasthenic syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 7 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD2 exomes AF: 0.00000402 AC: 1AN: 249026 AF XY: 0.00000740 show subpopulations
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1459686Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 725698 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Familial hyperkalemic periodic paralysis Uncertain:1
In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. This variant has not been reported in the literature in individuals affected with SCN4A-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.003%). This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 932 of the SCN4A protein (p.Asp932Tyr). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at